1www.brainstorm-cell.com

BrainStorm is a leading developer of stem cell

technologies to provide treatments for

currently incurable neurodegenerative diseases.

The Company is focused on developing NTF cells from the patient's own bone marrow in order to treat, Parkinson, ALS, and Spinal

Cord Injury.

www.brainstorm-cell.com

BrainStorm Cell Therapeutics BrainStorm Cell Therapeutics Inc. (OTCBB:  BCLI)Inc. (OTCBB:  BCLI)

3

Large and growing population of Parkinson Disease patients (4 M in the Western world).

Heavy social burden (according to NINDS, $26B in the U.S. annually).

Disease anatomy and pathology is well known, although causes are still obscure.

Affects a clearly defined region of the brain, the substantia nigra.

Parkinson DiseaseParkinson DiseasePD is a degenerative disorder of the central nervous system (loss of dopamine-containing nerve cells) that often impairs the sufferer's motor skills, speech and other functions.

4

Amyotrophic Lateral Sclerosis Amyotrophic Lateral Sclerosis DiseaseDisease

5,600 people in the U.S. are diagnosed with ALS Amyotrophic Lateral Sclerosis (Lou Gehrig's Disease) each year. Total 30,000 patients in the US. & 100,000 around the world.

Fatal progressive loss of motor neurons in brain and spinal cord. Leads to gradual loss of movement ability, culminating in death. One approved drug – Rilutek (Riluzole) affords only an additional

few months of life. Pressing need for new effective therapies.

ALS (sometimes called Lou Gehrig's disease) is a progressive, usually fatal, neurodegenerative disease caused by the degeneration of motor neurons, the nerve cells in the central nervous system that control voluntary muscle movement.

Cell technologies may offer a major improvement over medication, as they target the diseased cell or organ and

replace it with a healthy alternative.

Advantage of Cell Advantage of Cell TherapyTherapy

Adult stem cells are undifferentiated cells, found throughout the body after embryonic development, that multiply by cell division to replenish dying cells and regenerate damaged tissues.

Adult Stem CellsAdult Stem Cells

Adult Stem Cells (From Bone Marrow)

Advantages: Non tumor forming. More than 40 years safety record. Harvested from patient – therapy

does not require immunosupression. Unlike embryonic stem cells, the

use of adult stem cells in research and therapy is not considered to be controversial as they are derived from adult tissue samples rather than human embryos.6

7

Brainstorm’s Brainstorm’s strategystrategy

Bone marrow aspiration

Into neurotrophic factors(NTF) secreting cell

BrainStormPatent

BrainStorm know-how

Autologous Bone Marrow-derived Stem Cell Therapy

NurOwn™ Therapeutic TechnologyNurOwn™ Therapeutic TechnologyNurOwn™ Therapeutic TechnologyNurOwn™ Therapeutic Technology

www.brainstorm-cell.com

3. PCT covering methods of generating GDNF-producing cells from bone marrow stem cells; Currently in national phase

3. PCT covering methods of generating GDNF-producing cells from bone marrow stem cells; Currently in national phase

2. PCT covering methods of generating oligodendrocytes from bone marrow stem cells; Currently in national phase

2. PCT covering methods of generating oligodendrocytes from bone marrow stem cells; Currently in national phase

Intellectual PropertyIntellectual Property

1. PCT covering methods of generating Dopamine-producing neural cells from bone marrow stem cells; Currently in national phase (Patent granted in Singapore)

1. PCT covering methods of generating Dopamine-producing neural cells from bone marrow stem cells; Currently in national phase (Patent granted in Singapore)

8 www.brainstorm-cell.com

Trademark filed for NurOwnTM in the US 3 Patents pending

NTF cells NTF cells OligodendrocyteOligodendrocyteNeuron Neuron

Bone Marrow Stem Cells

Business Business ModelModel

NurOwnTM

Neurosurgery: NurOwn™

Cells implantation

Hematology:Bone Marrow

aspirate

Insurance payment to medical center

Patient population

Medical center purchases BrainStorm cell processing

services

9 www.brainstorm-cell.com

BrainStorm Financial BrainStorm Financial SummarySummary

Stock Symbol: OTCBB:BCLI

Shares outstanding: 55.3M

Current price of stock : ~ $0.1

52 week price range: $0.07-$0.76

Market capitalization: ~ $5M

Approximate Public Float: 17M shares

Monthly current burn rate : $150K

Seeking for $10M to complete phase I and II clinical trials in ALS

and phase I clinical trials in Parkinson.

www.brainstorm-cell.com10

11

Safe Harbor Safe Harbor DisclaimerDisclaimer

This presentation may contain certain ‘forward-looking statements’. All statements, other than statements of historical

fact, that address activities, events or developments that we intend, expect, project, believe or anticipate will or may occur in the future are forward-looking statements. Such statements are based upon certain assumptions and assessments made by our management in light of their experience and their perception of

historical trends, current conditions, expected future developments and other factors they believe to be appropriate.

The forward-looking statements included in this presentation are also subject to a number of material risks and uncertainties. We

caution investors not to place undue reliance on the forward-looking statements contained in this presentation.

We would advise reading our annual report filed with the United States Securities and Exchange Commission on Form 10-K for a

more detailed description of these risks.

www.brainstorm-cell.com

12 www.brainstorm-cell.com